NCT00046748.

Methods	Randomised, double‐blind, parallel‐group study
Participants	Adults and adolescents with severe persistent asthma
Interventions	Subcutaneous omalizumab versus placebo
Outcomes	Clinically significant asthma exacerbation Medical resource utilisation Time to first asthma exacerbation Quality of life assessment at baseline, last visit Frequency of asthma rescue medication use Safety/tolerability of omalizumab
Notes	No data available at time of completion of 2012 update of this review